

Supporting Information

Nickel-Catalyzed Cross-Coupling of Chromene Acetals and Boronic Acids

Thomas J. A. Graham, Abigail G. Doyle*

*Department of Chemistry, Princeton University
Frick Chemical Laboratory, Princeton, NJ 08544 USA*

E-mail: agdoyle@princeton.edu

Table of Contents

I.	General Information	S-2
II.	Procedure for preparation of 2-aryl and 2-heteroaryl-2 <i>H</i> -1-benzopyrans	S-4
III.	Procedure for gram scale synthesis of 2-phenyl-2 <i>H</i> -1-benzopyran	S-20
IV.	Procedure for the late stage addition of aryl boronic acids to chromene acetals	S-21
V.	Procedure for preparation of complex aryl boronic acids	S-24
VI.	Procedure for the preparation of chromene acetals	S-27
VII.	Competition study	S-29
VIII.	NMR Spectra	S-34

I. General Information

General Procedures. Unless otherwise noted, reactions were performed with rigorous exclusion of air or moisture. Ar-flushed stainless steel cannulae or gas-tight syringes were used to transfer air- and moisture-sensitive reagents. Solvent was freshly distilled/degassed prior to use unless otherwise noted. Reactions were monitored by LCMS. Organic solutions were concentrated under reduced pressure using a rotary evaporator (30 °C, <50 torr). Automated column chromatography was performed using pre-packed silica gel cartridges on a Biotage SP4 (40-53 μm , 60 Å).

Materials. Commercial reagents were used as received with the following exceptions. 4-CF₃-phenylboronic acid, 4-MeO-phenyl boronic acid and phenyl boronic acid were recrystallized from water and stored on the benchtop. 1,4-dioxane (inhibitor free, ACS reagent grade >99%), and toluene (ACS reagent grade, >99%) were freshly distilled from Na under an atmosphere of dry N₂ prior to use. Anhydrous 2-methyl-2-butanol (*t*-AmOH, 1 L Sure/Seal™ bottle) was purchased from Aldrich and sparged with N₂ for 30 min under sonication prior to use.

Ni(cod)₂ was purchased from Strem and stored at -40 °C in a N₂ filled glovebox. Triphenylphosphine was purchased from Strem and stored in a N₂ filled glovebox.

Instrumentation. Proton nuclear magnetic resonance (¹H NMR) spectra and carbon nuclear magnetic resonance (¹³C NMR) spectra were recorded on a Bruker 500 AVANCE spectrometer (500 and 125 MHz, respectively). Chemical shifts for protons are reported in parts per million downfield from tetramethylsilane and are referenced to residual protium in the NMR solvent (CHCl₃ = δ 7.26). Chemical shifts for carbon are reported in parts per million downfield from tetramethylsilane and are referenced to the carbon resonances of the solvent residual peak (CDCl₃ = δ 77.16 ppm). ¹⁹F spectra were recorded on a Varian Inova 300 (282 MHz) spectrometer; chemical shifts are reported in parts per millions and are referenced to CFCl₃ (δ 0 ppm). NMR data are represented as follows: chemical shift (δ ppm), multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet), coupling constant in Hertz (Hz), integration. FT-IR spectra were recorded on a Perkin-Elmer Paragon 500 and are reported in terms of frequency of absorption (cm⁻¹). LCMS was performed on an Agilent 1260 series instrument with a multimode detector (APCI/ESI). Prep HPLC was performed on an Agilent Prep-star with single wavelength UV detector.


II. Procedure for preparation of 2-aryl and 2-heteroaryl-2H-1-benzopyrans

General procedure:

A 2-dram vial equipped with a PTFE-coated stir-bar and PTFE-tape-lined screw-thread was brought into a N₂ filled glovebox, charged with Ni(cod)₂ (13.6 mg, 0.05 mmol, 10 mol%) and PPh₃ (13 mg, 0.05 mmol, 10 mol%; or 30 mol%). 1,4-dioxane (1 mL) was added via micropipette and the resulting orange suspension stirred until complete dissolution (15 min, dark blood red solution was formed). The vial was tightly sealed with a PTFE-lined screw-cap and the vial further sealed with electrical tape. It was removed from the glovebox and placed on an N₂ line.

A 50 mL pear-shaped Schlenk flask equipped with a PTFE-coated stir-bar was charged with 2-ethoxy-2H-chromene (88 mg, 0.50 mmol, or appropriate amount of substituted chromene acetal) and the appropriate arylboronic acid (1.00 mmol, 2 equiv.). The flask was sealed with a rubber septum and subjected to 3-4 evac/purge cycles (~45 sec per cycle). The flask was then charged with 1,4-dioxane (23 mL, freshly distilled from Na) and *t*-AmOH (2 mL, degassed by sparging with N₂ in a sonicator bath for 15-30 min) to give a homogenous solution (0.02M with respect to chromene acetal) (Some boronic acids did not completely dissolve. Reactivity/reproducibility was not affected.). The catalyst solution was then added via syringe and the resulting orange/yellow solution stirred at the appropriate temperature (r.t., 40 °C, or 100 °C) until complete conversion of 2-ethoxy-2H-chromene or stagnation was observed by LCMS.

After this time, the reaction mixture was concentrated and the crude subjected to flash chromatography.




Prepared according to the general procedure (r.t., 10 mol% PPh₃, complete conversion by LCMS after 2 h), the title compound was isolated as a yellow gum (Run 1: 117 mg, 88%; Run 2: 117 mg 88%).

IR (neat, cm⁻¹): 3300, 3048, 1664, 1514.

¹H NMR (500 MHz, CDCl₃): δ 7.49 (d, *J* = 8.4 Hz, 2H), 7.39 (d, *J* = 8.5 Hz, 2H), 7.10 (t, *J* = 7.8 Hz, 1H), 7.01 (d, *J* = 7.4 Hz, 1H), 6.86 (t, *J* = 7.4 Hz, 1H), 6.76 (d, *J* = 8.0 Hz, 1H), 6.54 (d, *J* = 9.8 Hz, 1H), 5.87 (s, 1H), 5.77 (dd, *J* = 9.8, 3.4 Hz, 1H), 2.16 (s, 3H).

¹³C NMR (125 MHz, CDCl₃): δ 168.53, 153.07, 138.06, 136.63, 129.59, 128.06, 126.71, 124.76, 124.23, 121.43, 121.33, 120.07, 116.14, 76.72, 24.75.

HRMS: (ESI-TOF) calculated for $C_{17}H_{16}NO_2$ ($[M+H]^+$): 266.1176, found: 266.1189.



Prepared according to the general procedure (r.t., 10 mol% PPh_3 , complete conversion by LCMS after 4 h), the title compound was isolated as a colorless oil (Run 1: 104 mg, 92%; Run 2: 105 mg, 93%).


IR (neat, cm^{-1}): 3044, 1603, 1508, 1221.

1H NMR (500 MHz, $CDCl_3$): δ 7.45 – 7.40 (m, 2H), 7.12 (td, $J = 7.9, 1.5$ Hz, 1H), 7.05 (t, $J = 8.7$ Hz, 2H), 7.02 (dd, $J = 7.5, 1.3$ Hz, 1H), 6.88 (t, $J = 7.4$ Hz, 1H), 6.77 (d, $J = 8.1$ Hz, 1H), 6.56 (dd, $J = 9.8, 1.6$ Hz, 1H), 5.90 (dd, $J = 2.8, 1.9$ Hz, 1H), 5.78 (dd, $J = 9.8, 3.4$ Hz, 1H).

^{13}C NMR (125 MHz, $CDCl_3$): δ 162.84 (d, $J = 246.9$ Hz), 152.99, 136.65 (d, $J = 3.2$ Hz), 129.71, 129.11 (d, $J = 8.3$ Hz), 126.77, 124.64, 124.42, 121.45, 121.34, 116.16, 115.68 (d, $J = 21.5$ Hz), 76.50.

^{19}F NMR (282 MHz, $CDCl_3$): δ -114.11.

HRMS: (ESI-TOF) calculated for $C_{15}H_{12}FO$ ($[M+H]^+$): 227.0867, found: 227.0872.




Prepared according to the general procedure (40 °C, 10 mol% PPh_3 , complete conversion by LCMS after 4 h), the title compound was isolated as a colorless oil (Run 1: 131 mg, 93%; Run 2: 135 mg, 96%).

IR (neat, cm^{-1}): 3044, 2903, 1712, 1290.

1H NMR (500 MHz, $CDCl_3$): δ 8.04 (d, $J = 7.6$ Hz, 2H), 7.52 (d, $J = 7.8$ Hz, 2H), 7.13 (t, $J = 7.7$ Hz, 1H), 7.02 (d, $J = 7.4$ Hz, 1H), 6.88 (t, $J = 7.4$ Hz, 1H), 6.81 (d, $J = 8.1$ Hz, 1H), 6.55 (d, $J = 9.8$ Hz, 1H), 5.97 (s, 1H), 5.80 (dd, $J = 9.8, 3.4$ Hz, 1H), 4.37 (q, $J = 7.1$ Hz, 2H), 1.38 (t, $J = 7.1$ Hz, 3H).

^{13}C NMR (125 MHz, $CDCl_3$): δ 166.44, 153.07, 145.74, 130.47, 130.08, 129.80, 126.86, 126.82, 124.52, 124.29, 121.59, 121.33, 116.14, 76.58, 61.15, 14.47.

HRMS: (ESI-TOF) calculated for $C_{18}H_{17}O_3$ ($[M+H]^+$): 281.1172, found: 281.1169.



Prepared according to the general procedure (40 °C, 10 mol% PPh₃, complete conversion by LCMS after 1 h), the title compound was isolated as a white solid (Run 1: 122 mg, 88%; Run 2: 123 mg, 89%).


IR (neat, cm⁻¹): 3051, 1485, 1310, 1067.

¹H NMR (500 MHz, CDCl₃): δ 7.63 (d, *J* = 8.0 Hz, 2H), 7.57 (d, *J* = 8.0 Hz, 2H), 7.14 (t, *J* = 7.7 Hz, 1H), 7.02 (d, *J* = 7.4 Hz, 1H), 6.89 (t, *J* = 7.4 Hz, 1H), 6.81 (d, *J* = 8.1 Hz, 1H), 6.56 (d, *J* = 9.8 Hz, 1H), 5.97 (s, 1H), 5.79 (dd, *J* = 9.8, 3.3 Hz, 1H).

¹³C NMR (125 MHz, CDCl₃): δ 152.92, 144.79, 130.50 (q, *J* = 32.4 Hz), 129.87, 127.27, 126.91, 125.77 (q, *J* = 3.7 Hz), 124.68, 124.15 (q, *J* = 272.2 Hz), 124.05, 121.67, 121.24, 116.14, 76.33.

¹⁹F NMR (282 MHz, CDCl₃): δ -63.01.

HRMS: (ESI-TOF) calculated for C₁₆H₁₂F₃O ([M+H]⁺): 277.0835, found: 277.0849.



Prepared according to the general procedure (r.t., 10 mol% PPh₃, reaction stagnates by LCMS after 4 h), the title compound was isolated as a colorless oil (Run 1: 122 mg, 86%; Run 2: 132 mg, 89%).


IR (neat, cm⁻¹): 3045, 1485, 1253, 1150.

¹H NMR (500 MHz, CDCl₃): δ 7.41 – 7.38 (m, 2H), 7.31 (s, 1H), 7.17 (d, *J* = 4.5 Hz, 1H), 7.14 (t, *J* = 7.8 Hz, 1H), 7.03 (d, *J* = 7.4 Hz, 1H), 6.89 (td, *J* = 7.4, 0.8 Hz, 1H), 6.81 (d, *J* = 8.1 Hz, 1H), 6.57 (d, *J* = 9.8 Hz, 1H), 5.93 (s, 1H), 5.79 (dd, 1H).

¹³C NMR (125 MHz, CDCl₃): δ 152.91, 149.54 (q, *J* = 1.6 Hz), 143.25, 130.19, 129.82, 126.87, 125.36, 124.71, 124.11, 121.63, 121.26, 120.76, 120.54 (q, *J* = 257.4 Hz), 119.70, 116.16, 76.24.

¹⁹F NMR (282 MHz, CDCl₃): δ -58.17.

HRMS: (ESI-TOF) calculated for C₁₆H₁₂F₃O₂ ([M+H]⁺): 293.0784, found: 293.0787.



Prepared according to the general procedure (r.t., 10 mol% PPh₃, reaction stagnates by LCMS after 4 h), the title compound was isolated as a colorless oil (Run 1: 115 mg, 79%, Run 2: 103 mg, 70%).


IR (neat, cm⁻¹): 3045, 1485, 1253, 1150.

¹H NMR (500 MHz, CDCl₃): δ 7.49 (d, *J* = 8.6 Hz, 2H), 7.21 (d, *J* = 8.3 Hz, 2H), 7.17 – 7.08 (m, 1H), 7.03 (d, *J* = 7.4 Hz, 1H), 6.89 (t, *J* = 7.4 Hz, 1H), 6.79 (d, *J* = 8.1 Hz, 1H), 6.56 (d, *J* = 9.8 Hz, 1H), 5.92 (m, 1H), 5.78 (dd, *J* = 9.8, 3.4 Hz, 1H).

¹³C NMR (125 MHz, CDCl₃): δ 152.93, 149.21 (*q*, *J* = 2.0 Hz), 139.55, 129.79, 128.68, 126.84, 124.55, 124.34, 123.60, 121.57, 121.29, 120.46 (*q*, *J* = 275.8 Hz), 117.47, 116.15, 76.32.

¹⁹F NMR (282 MHz, CDCl₃): δ -58.25.

HRMS: (ESI-TOF) calculated for C₁₆H₁₂F₃O₂ ([M+H]⁺): 293.0784, found: 293.0792.




Prepared according to the general procedure (40 °C, 10 mol% PPh₃, reaction stagnates by LCMS after 4 h), the title compound was isolated as a colorless oil (Run 1: 81 mg, 66%, Run 2: 83 mg, 68%).

IR (neat, cm⁻¹): 3045, 1603, 1484, 1226.

¹H NMR (500 MHz, CDCl₃): δ 7.39 (d, *J* = 8.5 Hz, 2H), 7.34 (d, *J* = 8.5 Hz, 2H), 7.12 (td, *J* = 7.8, 1.6 Hz, 1H), 7.01 (dd, *J* = 7.4, 1.5 Hz, 1H), 6.88 (td, *J* = 7.4, 0.8 Hz, 1H), 6.78 (d, *J* = 8.1 Hz, 1H), 6.55 (dd, *J* = 9.8, 1.5 Hz, 1H), 5.89 (dd, *J* = 3.2, 1.8 Hz, 1H), 5.77 (dd, *J* = 9.8, 3.5 Hz, 1H).


¹³C NMR (125 MHz, CDCl₃): δ 152.99, 139.36, 134.33, 129.76, 128.96, 128.58, 126.81, 124.52, 124.38, 121.51, 121.33, 116.17, 76.40.

HRMS: (ESI-TOF) calculated for C₁₅H₁₂ClO ([M+H]⁺): 243.0571, found: 243.0557.



Prepared according to the general procedure (r.t., 10 mol% PPh₃, complete conversion by LCMS after 4 h), the title compound was isolated as a colorless oil (Run #1: 101 mg, 86%, Run #2: 101 mg, 86%). Spectroscopic data was in complete agreement with previously published results. (Conducting this reaction in the absence of Ni(cod)₂/PPh₃ resulted in no reaction.)

Ref: Moquist, P. N.; Kodama, T.; Schaus, S. E. *Angew. Chem., Int. Ed. Engl.* **2010**, *49*, 7096.




Prepared according to the general procedure (r.t., 10 mol% PPh₃, complete conversion by LCMS after 4 h), the title compound was isolated as a colorless oil (Run 1: 125 mg, 97%; Run 2: 125 mg, 97%).

IR (neat, cm⁻¹): 3044, 1605, 1484, 1224.

¹H NMR (500 MHz, CDCl₃): δ 8.32 (d, *J* = 8.3 Hz, 1H), 7.90 (d, *J* = 8.0 Hz, 1H), 7.84 (d, *J* = 8.2 Hz, 1H), 7.66 (d, *J* = 7.1 Hz, 1H), 7.54 (dt, *J* = 14.8, 7.1 Hz, 2H), 7.46 (t, *J* = 7.6 Hz, 1H), 7.11 (t, *J* = 7.7 Hz, 1H), 7.08 (d, *J* = 7.4 Hz, 1H), 6.90 (t, *J* = 7.4 Hz, 1H), 6.79 (d, *J* = 8.0 Hz, 1H), 6.65 (d, *J* = 9.9 Hz, 1H), 6.62 (s, 1H), 5.92 (d, *J* = 9.8 Hz, 1H).

¹³C NMR (125 MHz, CDCl₃): δ 153.65, 135.56, 134.29, 131.07, 129.60, 129.30, 128.96, 126.84, 126.51, 125.99, 125.91, 125.44, 125.02, 124.95, 124.18, 121.77, 121.49, 116.31, 74.97.

HRMS: (ESI-TOF) calculated for C₁₉H₁₅O ([M+H]⁺): 259.1117, found: 259.1120.




Prepared according to the general procedure (40 °C, 10 mol% PPh₃, complete conversion by LCMS after 1 h), the title compound was isolated as a pale yellow oil (Run 1: 131 mg, 97%, Run 2: 122 mg, 93%).

IR (neat, cm⁻¹): 3317, 3058, 1660, 1548.

¹H NMR (500 MHz, CDCl₃): δ 7.75 (d, *J* = 8.3 Hz, 2H), 7.51 (d, *J* = 8.2 Hz, 2H), 7.12 (td, *J* = 7.8, 1.6 Hz, 1H), 7.02 (dd, *J* = 7.4, 1.5 Hz, 1H), 6.88 (td, *J* = 7.4, 0.9 Hz, 1H), 6.80 (d, *J* = 8.1 Hz, 1H), 6.55 (dd, *J* = 9.8, 1.7 Hz, 1H), 6.11 (s, 1H), 5.97 – 5.93 (m, 1H), 5.79 (dd, *J* = 9.8, 3.5 Hz, 1H), 3.01 (d, *J* = 4.9 Hz, 3H).

¹³C NMR (125 MHz, CDCl₃): δ 167.93, 153.02, 144.21, 134.62, 129.77, 127.34, 127.19, 126.85, 124.50, 124.34, 121.57, 121.33, 116.13, 76.54, 27.02.

HRMS: (ESI-TOF) calculated for $C_{17}H_{16}NO_2$ ($[M+H]^+$): 266.1176, found: 266.1183.




Prepared according to the general procedure (r.t., 10 mol% PPh_3 , complete conversion by LCMS after 4 h), the title compound was isolated as a colorless oil (Run 1: 117 mg, 90%, Run 2: 116 mg, 89%).

IR (neat, cm^{-1}): 3054, 1602, 1484, 1226.

1H NMR (500 MHz, $CDCl_3$): δ 7.90 – 7.80 (m, 4H), 7.61 (d, $J = 8.4$ Hz, 1H), 7.52 – 7.45 (m, 2H), 7.12 (t, $J = 7.7$ Hz, 1H), 7.04 (d, $J = 7.2$ Hz, 1H), 6.88 (t, $J = 7.4$ Hz, 1H), 6.81 (d, $J = 8.0$ Hz, 1H), 6.59 (d, $J = 9.8$ Hz, 1H), 6.09 (s, 1H), 5.88 (dd, $J = 9.8, 3.2$ Hz, 1H).

^{13}C NMR (125 MHz, $CDCl_3$): δ 153.30, 138.18, 133.43, 133.33, 129.68, 128.76, 128.33, 127.83, 126.79, 126.38, 126.20, 125.09, 124.84, 124.39, 121.48, 121.38, 116.17, 77.40. One peak is obscured due to overlap.

HRMS: (ESI-TOF) calculated for $C_{19}H_{15}O$ ($[M+H]^+$): 259.1117, found: 259.1125.




Prepared according to the general procedure (40 °C, 10 mol% PPh_3 , reaction stagnates by LCMS after 2 h), the title compound was isolated as a pale yellow oil (Run 1: 83 mg, 54%, Run 2: 75 mg, 51%).

IR (neat, cm^{-1}): 3280, 3044, 2934, 1636.

1H NMR (500 MHz, $CDCl_3$): δ 7.75 (s, 1H), 7.63 (d, $J = 7.7$ Hz, 1H), 7.56 (d, $J = 7.7$ Hz, 1H), 7.41 (t, $J = 7.7$ Hz, 1H), 7.11 (td, $J = 7.8, 1.5$ Hz, 1H), 7.01 (dd, $J = 7.4, 1.5$ Hz, 1H), 6.87 (t, $J = 7.4$ Hz, 1H), 6.78 (d, $J = 8.0$ Hz, 1H), 6.56 (dd, $J = 9.8, 1.6$ Hz, 1H), 5.95 (dd, $J = 3.2, 1.8$ Hz, 1H), 5.81 (dd, $J = 9.8, 3.5$ Hz, 1H), 3.48 (s, 3H), 3.33 (s, 3H).

^{13}C NMR (125 MHz, $CDCl_3$): δ 169.77, 161.95, 153.03, 140.72, 134.50, 129.67, 129.38, 128.58, 128.29, 126.94, 126.80, 124.52, 124.46, 121.46, 121.43, 116.17, 76.72, 61.18.

HRMS: (ESI-TOF) calculated for $C_{18}H_{18}NO_3$ ($[M+H]^+$): 296.1281, found: 296.1285.




Prepared according to the general procedure (40 °C, 10 mol% PPh₃, complete conversion by LCMS after 1 h), the title compound was isolated as a white solid (Run 1: 124 mg, 99%, Run 2: 120 mg, 96%).

IR (neat, cm⁻¹): 3043, 1679, 1605, 1484.

¹H NMR (500 MHz, CDCl₃): δ 7.96 (d, *J* = 8.0 Hz, 2H), 7.55 (d, *J* = 8.0 Hz, 2H), 7.13 (t, *J* = 7.7 Hz, 1H), 7.02 (d, *J* = 7.4 Hz, 1H), 6.89 (t, *J* = 7.4 Hz, 1H), 6.81 (d, *J* = 8.1 Hz, 1H), 6.55 (d, *J* = 9.8 Hz, 1H), 5.97 (s, 1H), 5.80 (dd, *J* = 9.8, 3.4 Hz, 1H), 2.59 (s, 3H).

¹³C NMR (125 MHz, CDCl₃): δ 197.86, 153.04, 146.04, 137.03, 129.83, 128.90, 127.05, 126.90, 124.59, 124.15, 121.63, 121.30, 116.14, 76.50, 26.84.

HRMS: (ESI-TOF) calculated for C₁₇H₁₂F₃O ([M+H]⁺): 251.1067, found: 251.1071.



Prepared according to the general procedure (40 °C, 10 mol% PPh₃, complete conversion by LCMS after 1.5 h), the title compound was isolated as a colorless oil (Run 1: 134 mg, 97%; Run 2: 126 mg, 91%).


IR (neat, cm⁻¹): 3046, 1606, 1484, 1327.

¹H NMR (500 MHz, CDCl₃): δ 7.71 (s, 1H), 7.66 (d, *J* = 7.6 Hz, 1H), 7.59 (d, *J* = 7.7 Hz, 1H), 7.50 (t, *J* = 7.7 Hz, 1H), 7.14 (td, *J* = 8.0, 1.4 Hz, 1H), 7.03 (dd, *J* = 7.4, 1.1 Hz, 1H), 6.89 (t, *J* = 7.4 Hz, 1H), 6.81 (d, *J* = 8.1 Hz, 1H), 6.58 (dd, *J* = 9.8, 1.1 Hz, 1H), 5.97 (s, 1H), 5.80 (dd, *J* = 9.8, 3.3 Hz, 1H).

¹³C NMR (125 MHz, CDCl₃): δ 152.80, 141.81, 130.96 (q, *J* = 32.5 Hz), 130.39, 129.76, 129.21, 126.80, 125.17 (q, *J* = 3.7 Hz), 124.77, 124.14 (q, *J* = 272.0 Hz), 123.94, 123.82 (q, *J* = 3.8 Hz), 121.57, 121.14, 116.05, 76.32.

¹⁹F NMR (282 MHz, CDCl₃): δ -63.01.

HRMS: (ESI-TOF) calculated for C₁₆H₁₂F₃O ([M+H]⁺): 277.0835, found: 277.0837.



Prepared according to the general procedure (40 °C, 10 mol% PPh₃, complete conversion by LCMS after 1.5 h), the title compound was isolated as a white solid (Run 1: 122 mg, 93%; Run 2: 124 mg, 95%).


IR (neat, cm⁻¹): 3046, 1620, 1525, 1200.

¹H NMR (500 MHz, CDCl₃): δ 7.14 (t, *J* = 7.7 Hz, 1H), 7.08 (t, *J* = 7.0 Hz, 2H), 7.02 (d, *J* = 7.4 Hz, 1H), 6.90 (t, *J* = 7.4 Hz, 1H), 6.80 (d, *J* = 8.1 Hz, 1H), 6.59 (d, *J* = 9.8 Hz, 1H), 5.82 (s, 1H), 5.75 (dd, *J* = 9.8, 3.4 Hz, 1H).

¹³C NMR (125 MHz, CDCl₃): δ 152.46, 151.35 (ddd, *J* = 250.8, 10.1, 3.7 Hz), 139.64 (dt, *J* = 252.1, 15.4 Hz), 137.03 (dd, *J* = 10.6, 6.2 Hz), 130.01, 126.99, 125.23, 123.09, 121.87, 121.04, 116.21, 111.26 (dd, *J* = 16.6, 5.1 Hz), 75.23.

¹⁹F NMR (282 MHz, CDCl₃): δ -133.82 – -133.97 (m), -161.08 (tt, *J* = 20.5, 6.4 Hz).

HRMS: (ESI-TOF) calculated for C₁₅H₉F₃O ([M+H]⁺): 263.0678, found: 263.0679.



Prepared according to the general procedure (100 °C, 30 mol% PPh₃, >90% conversion (estimated) by LCMS after 30 min), the title compound was isolated as a colorless oil (Run 1: 98 mg, 71%; Run 2: 98 mg, 71%).


IR (neat, cm⁻¹): 3045, 1606, 1485, 1310.

¹H NMR (500 MHz, CDCl₃): δ 7.89 (d, *J* = 7.9 Hz, 1H), 7.71 (d, *J* = 7.9 Hz, 1H), 7.60 (t, *J* = 7.6 Hz, 1H), 7.46 (t, *J* = 7.7 Hz, 1H), 7.17 (t, *J* = 7.7 Hz, 1H), 7.06 (d, *J* = 7.4 Hz, 1H), 6.93 (t, *J* = 7.4 Hz, 1H), 6.82 (d, *J* = 8.1 Hz, 1H), 6.53 (dd, *J* = 9.9, 1.3 Hz, 1H), 6.39 (s, 1H), 5.69 (dd, *J* = 9.9, 2.8 Hz, 1H).

¹³C NMR (125 MHz, CDCl₃): δ 153.15, 139.95, 132.45, 129.72, 129.33, 128.26, 126.81 (q, *J* = 30.5 Hz), 126.74, 125.69 (q, *J* = 5.7 Hz), 124.63, 124.19 (q, *J* = 274.0 Hz), 123.81, 121.44, 120.75, 115.84, 73.19.

¹⁹F NMR (282 MHz, CDCl₃): δ -58.49.

HRMS: (ESI-TOF) calculated for $C_{16}H_{12}F_3O$ ($[M+H]^+$): 277.0835, found: 277.0854.




Prepared according to the general procedure (100 °C, 30 mol% PPh_3 , complete conversion by LCMS after 30 min), the title compound was isolated as a colorless oil (Run 1: 94 mg, 79%; Run 2: 102 mg, 87% (product inseparable from PPh_3 , yield is approximated based on NMR purity).

IR (neat, cm^{-1}): 3023, 2925, 1603, 1483.

1H NMR (500 MHz, $CDCl_3$): δ 7.07 – 7.01 (m, 2H), 6.96 (d, $J = 7.5$ Hz, 2H), 6.94 – 6.91 (m, 1H), 6.79 (t, $J = 7.4$ Hz, 1H), 6.70 (d, $J = 8.0$ Hz, 1H), 6.41 – 6.36 (m, 2H), 5.58 – 5.54 (m, 1H), 2.35 (s, 6H).

^{13}C NMR (125 MHz, $CDCl_3$): δ 154.30, 137.60, 136.20, 129.58, 129.44, 128.37, 126.84, 125.20, 124.85, 121.57, 121.32, 115.89, 74.48, 20.93.

HRMS: (ESI-TOF) calculated for $C_{17}H_{17}O$ ($[M+H]^+$): 237.1274, found: 237.1275.




Prepared according to the general procedure (100 °C, 30 mol% PPh_3 , >90% conversion (estimated) by LCMS after 30 min), the title compound was isolated as a colorless oil (Run #1: 101 mg, 71%, Run #2: 120 mg, 85%) (product inseparable from PPh_3 , yield is approximated based on NMR purity).

IR (neat, cm^{-1}): 3055, 1603, 1482, 1225.

1H NMR (500 MHz, $CDCl_3$): δ 7.76 – 7.70 (m, 1H), 7.48 – 7.30 (m, 8H), 7.11 (t, $J = 7.7$ Hz, 1H), 6.99 (d, $J = 7.4$ Hz, 1H), 6.85 (t, $J = 7.4$ Hz, 1H), 6.78 (d, $J = 8.0$ Hz, 1H), 6.49 (d, $J = 9.9$ Hz, 1H), 6.00 (s, 1H), 5.65 (dd, $J = 9.9, 2.6$ Hz, 1H).

^{13}C NMR (125 MHz, $CDCl_3$): δ 153.30, 141.36, 140.52, 138.02, 130.39, 129.65, 129.59, 128.60, 128.41, 128.36, 128.09, 127.44, 126.64, 125.45, 124.06, 121.37, 121.23, 116.08, 74.17.

HRMS: (ESI-TOF) calculated for $C_{21}H_{17}O$ ($[M+H]^+$): 285.1274, found: 285.1273.



Prepared according to the general procedure (100 °C, 30 mol% PPh₃, complete conversion by LCMS after 30 min), the title compound was isolated as a colorless oil (Run #1: 144 mg, 84%, Run #2: 146 mg, 86%).


IR (neat, cm⁻¹): 3060, 1486, 1273, 1083.

¹H NMR (500 MHz, CDCl₃): δ 8.03 (d, *J* = 8.2 Hz, 1H), 7.95 (s, 1H), 7.83 (d, *J* = 8.2 Hz, 1H), 7.17 (td, *J* = 7.9, 1.3 Hz, 1H), 7.05 (dd, *J* = 7.4, 1.1 Hz, 1H), 6.93 (t, *J* = 7.4 Hz, 1H), 6.80 (d, *J* = 8.1 Hz, 1H), 6.54 (dd, *J* = 9.9, 1.8 Hz, 1H), 6.39 (s, 1H), 5.63 (dd, *J* = 9.8, 2.8 Hz, 1H).

¹³C NMR (125 MHz, CDCl₃): δ 152.91, 144.04, 130.82 (q, *J* = 33.4 Hz), 130.33, 130.14, 129.42 (q, *J* = 3.2 Hz), 127.63 (q, *J* = 31.9 Hz), 127.05, 124.56, 123.72, 123.50 (q, *J* = 274.5 Hz), 123.36 (q, *J* = 272.8 Hz), 123.26 – 122.98 (m), 121.93, 120.61, 115.98, 72.95.

¹⁹F NMR (282 MHz, CDCl₃): δ -58.86, -63.20.

HRMS: (ESI-TOF) calculated for C₁₇H₁₁F₂O ([M+H]⁺): 345.0709, found: 345.0715.




Prepared according to the general procedure (40 °C, 10 mol% PPh₃, complete conversion by LCMS after 3 h), the title compound was isolated as a colorless oil (Run #1: 104 mg, 94%, Run #2: 106 mg, 96%).

IR (neat, cm⁻¹): 3024, 2955, 1604, 1483.

¹H NMR (500 MHz, CDCl₃): δ 7.48 (d, *J* = 7.0 Hz, 1H), 7.24 – 7.18 (m, 3H), 7.11 (t, *J* = 7.3 Hz, 1H), 7.02 (d, *J* = 7.3 Hz, 1H), 6.87 (t, *J* = 7.4 Hz, 1H), 6.77 (d, *J* = 8.0 Hz, 1H), 6.57 (dd, *J* = 9.8, 1.9 Hz, 1H), 6.17 – 6.13 (m, 1H), 5.75 (dd, *J* = 9.8, 3.1 Hz, 1H), 2.47 (s, 3H).

¹³C NMR (125 MHz, CDCl₃): δ 153.59, 138.40, 136.06, 130.97, 129.54, 128.46, 127.84, 126.72, 126.34, 124.68, 124.61, 121.54, 121.29, 116.06, 74.80, 19.38.

HRMS: (ESI-TOF) calculated for C₁₆H₁₄O ([M+H]⁺): 223.1117, found: 223.1122.




Prepared according to the general procedure (40 °C, 10 mol% PPh₃, reaction stagnates by LCMS after 4.5 h), the title compound was isolated as a beige solid (Run #1: 68 mg, 52%, Run #2: 88 mg, 68%).

IR (neat, cm⁻¹): 3015, 2900, 1601, 1484.

¹H NMR (500 MHz, CDCl₃): δ 7.69 (s, 1H), 7.34 (dd, *J* = 19.7, 8.5 Hz, 2H), 7.11 – 7.00 (m, 3H), 6.85 (t, *J* = 7.2 Hz, 1H), 6.75 (d, *J* = 8.0 Hz, 1H), 6.56 (d, *J* = 9.9 Hz, 1H), 6.47 (d, *J* = 2.9 Hz, 1H), 6.03 (s, 1H), 5.86 (dd, *J* = 9.8, 3.3 Hz, 1H), 3.79 (s, 3H).

¹³C NMR (125 MHz, CDCl₃): δ 153.37, 136.83, 131.79, 129.58, 129.44, 128.50, 126.59, 125.72, 123.78, 121.57, 121.39, 121.01, 120.20, 116.19, 109.62, 101.43, 78.22, 33.09.

HRMS: (ESI-TOF) calculated for C₁₈H₁₆NO ([M+H]⁺): 262.1226, found: 262.1234.




Prepared according to the general procedure (100 °C, 30 mol% PPh₃, complete conversion by LCMS after 1h), the title compound was isolated as a colorless oil (Run #1: 80 mg, 67%, Run #2: 82 mg, 69%).

IR (neat, cm⁻¹): 3044, 1603, 1484, 1224.

¹H NMR (500 MHz, CDCl₃): δ 8.20 (d, *J* = 2.4 Hz, 1H), 7.68 (dd, *J* = 8.6, 2.5 Hz, 1H), 7.10 (td, *J* = 7.8, 1.6 Hz, 1H), 7.02 (dd, *J* = 7.5, 1.6 Hz, 1H), 6.87 (td, *J* = 7.4, 1.1 Hz, 1H), 6.74 (d, *J* = 8.0 Hz, 1H), 6.73 (d, *J* = 8.6 Hz, 1H), 6.59 (dd, *J* = 9.8, 1.4 Hz, 1H), 5.87 (dd, *J* = 3.5, 1.7 Hz, 1H), 5.77 (dd, *J* = 9.8, 3.6 Hz, 1H), 3.93 (s, 3H).

¹³C NMR (125 MHz, CDCl₃): δ 164.46, 152.82, 146.06, 138.18, 129.77, 128.96, 126.80, 124.91, 123.98, 121.52, 121.42, 116.30, 111.26, 74.64, 53.68.

HRMS: (ESI-TOF) calculated for C₁₅H₁₄NO₂ ([M+H]⁺): 240.1019, found: 240.1026.




Prepared according to the general procedure (100 °C, 30 mol% PPh₃, the reaction stagnates by LCMS after 1.5 h), the title compound was isolated as a colorless oil (Run #1: 67 mg, 50%, Run #2 71 mg, 53%). (After column chromatography, the title compound was further purified by prep. HPLC 50:50 MeCN:H₂O to 100:0 MeCN:H₂O to remove protodeborylated material.)

IR (neat, cm⁻¹): 2946, 1586, 1479, 1202.

¹H NMR (500 MHz, CDCl₃): δ 7.62 (d, *J* = 8.1 Hz, 1H), 7.09 (td, *J* = 8.1, 1.3 Hz, 1H), 6.99 (dd, *J* = 7.5, 1.1 Hz, 1H), 6.85 (t, *J* = 7.4 Hz, 1H), 6.77 (d, *J* = 8.0 Hz, 1H), 6.52 (d, *J* = 9.8 Hz, 1H), 6.25 (d, *J* = 8.1 Hz, 1H), 6.18 (s, 1H), 5.74 (dd, *J* = 9.8, 3.6 Hz, 1H), 3.98 (s, 3H), 3.91 (s, 3H).

¹³C NMR (125 MHz, CDCl₃): δ 162.97, 159.45, 153.29, 139.93, 129.47, 126.64, 124.40, 124.04, 121.46, 121.20, 116.21, 113.92, 100.87, 70.86, 53.78, 53.66.

HRMS: (ESI-TOF) calculated for C₁₆H₁₆NO₃ ([M+H]⁺): 270.1125, found: 270.1132.



Prepared according to the general procedure (100 °C, 30 mol% PPh₃, complete conversion by LCMS after 1h), the title compound was isolated as a colorless oil (Run #1: 113 mg, 81%, Run #2: 114 mg, 82%).


IR (neat, cm⁻¹): 3056, 1606, 1485, 1334.

¹H NMR (500 MHz, CDCl₃): δ 8.80 (s, 1H), 7.97 (d, *J* = 8.1 Hz, 1H), 7.68 (d, *J* = 8.1 Hz, 1H), 7.15 (td, *J* = 7.9, 1.2 Hz, 1H), 7.04 (dd, *J* = 7.5, 1.0 Hz, 1H), 6.91 (t, *J* = 7.4 Hz, 1H), 6.81 (d, *J* = 8.1 Hz, 1H), 6.64 (d, *J* = 9.8 Hz, 1H), 6.03 (s, 1H), 5.82 (dd, *J* = 9.8, 3.7 Hz, 1H).

¹³C NMR (125 MHz, CDCl₃): δ 152.41, 148.81, 148.07 (q, *J* = 34.8 Hz), 139.42, 136.06, 130.18, 127.09, 125.63, 122.71, 122.07, 121.54 (q, *J* = 274.1 Hz), 121.12, 120.59 (q, *J* = 2.6 Hz), 116.31, 73.97.

¹⁹F NMR (282 MHz, CDCl₃): δ -68.32.

HRMS: (ESI-TOF) calculated for C₁₅H₁₁F₃NO ([M+H]⁺): 278.0787, found: 278.0793.




Prepared according to the general procedure (rt., 10 mol% PPh₃, >65% conversion (estimated) by LCMS after 1h). The reaction was allowed to stir overnight before workup (at 24h the reaction shows >99% conv. by LCMS), the title compound was isolated as a colorless oil (Run #1: 101 mg, 91%, Run #2: 103 mg, 93%).

IR (neat, cm⁻¹): 3029, 2918, 1488, 1210.

¹H NMR (500 MHz, CDCl₃): δ 7.45 (d, *J* = 7.1 Hz, 2H), 7.40 – 7.30 (m, 3H), 6.92 (dd, *J* = 8.0, 1.3 Hz, 1H), 6.83 (s, 1H), 6.70 (d, *J* = 8.1 Hz, 1H), 6.50 (dd, *J* = 9.8, 1.3 Hz, 1H), 5.88 (s, 1H), 5.80 (dd, *J* = 9.8, 3.4 Hz, 1H), 2.26 (s, 3H).

¹³C NMR (125 MHz, CDCl₃): δ 151.03, 140.98, 130.51, 130.00, 128.78, 128.45, 127.19, 127.16, 125.09, 124.25, 121.23, 115.83, 77.18, 20.69.

HRMS: (ESI-TOF) calculated for C₁₆H₁₅O ([M+H]⁺): 223.1117, found: 223.1109.



Prepared according to the general procedure (rt., 10 mol% PPh₃, >99% conversion by LCMS after 24h), the title compound was isolated as a colorless oil (Run #1: 101 mg, 90%, Run #2: 107 mg, 95%).


IR (neat, cm⁻¹): 3056, 2908, 1441, 1203.

¹H NMR (500 MHz, CDCl₃): δ 7.44 (d, *J* = 7.5 Hz, 2H), 7.40 – 7.32 (m, 3H), 6.80 (td, *J* = 8.5, 3.0 Hz, 1H), 6.76 – 6.70 (m, 2H), 6.50 (dd, *J* = 10.8, 3.0 Hz, 1H), 5.92 – 5.84 (m, 2H).

¹³C NMR (125 MHz, CDCl₃): δ 157.45 (d, *J* = 238.3 Hz), 149.04 (d, *J* = 2.2 Hz), 140.36, 128.84, 128.67, 127.20, 126.46, 123.65, 122.40 (d, *J* = 8.3 Hz), 116.97 (d, *J* = 8.0 Hz), 115.56 (d, *J* = 23.2 Hz), 112.87 (d, *J* = 23.8 Hz), 77.24.

¹⁹F NMR (282 MHz, CDCl₃): δ -123.66.

HRMS: (ESI-TOF) calculated for C₁₅H₁₂FO ([M+H]⁺): 227.0867, found: 227.0873.




Prepared according to the general procedure (r.t., 10 mol% PPh₃, >80% conversion by LCMS (estimated) after 24h), the title compound was isolated as a colorless oil (Run #1: 94 mg, 78%, Run #2: 99 mg, 82%).

IR (neat, cm⁻¹): 3046, 1473, 1193, 1025.

¹H NMR (500 MHz, CDCl₃): δ 7.43 (d, *J* = 6.9 Hz, 2H), 7.41 – 7.31 (m, 3H), 7.05 (dd, *J* = 8.6, 2.5 Hz, 1H), 6.99 (d, *J* = 2.4 Hz, 1H), 6.71 (d, *J* = 8.6 Hz, 1H), 6.49 (d, *J* = 9.8 Hz, 1H), 5.91 (s, 1H), 5.86 (dd, *J* = 9.8, 3.4 Hz, 1H).

¹³C NMR (125 MHz, CDCl₃): δ 151.70, 140.28, 129.14, 128.88, 128.74, 127.19, 126.26, 126.17, 125.93, 123.25, 122.71, 117.44. One peak is obscured due to overlap.

HRMS: (ESI-TOF) calculated for C₁₅H₁₂ClO ([M+H]⁺): 243.0571, found: 243.0566.




Prepared according to the general procedure (r.t., 10 mol% PPh₃, ~90% conversion by LCMS (estimated) after 16h), the title compound was isolated as a yellow oil (Run #1: 90 mg, 75%, Run #2: 90 mg, 75%).

IR (neat, cm⁻¹): 3030, 1611, 1503, 1270.

¹H NMR (500 MHz, CDCl₃): δ 7.45 (d, *J* = 7.2 Hz, 2H), 7.40 – 7.30 (m, 3H), 6.93 (d, *J* = 8.3 Hz, 1H), 6.50 (dd, *J* = 9.7, 1.1 Hz, 1H), 6.43 (dd, *J* = 8.3, 2.4 Hz, 1H), 6.39 (s, 1H), 5.89 (s, 1H), 5.67 (dd, *J* = 9.8, 3.3 Hz, 1H), 3.75 (s, 3H).

¹³C NMR (125 MHz, CDCl₃): δ 160.97, 154.46, 141.00, 128.80, 128.51, 127.40, 127.20, 123.77, 121.99, 114.74, 107.14, 101.89, 77.44, 55.46.

HRMS: (ESI-TOF) calculated for C₁₆H₁₅O₂ ([M+H]⁺): 239.1067, found: 239.1064.



Prepared according to the general procedure (100 °C, 30 mol% PPh₃, reaction stagnates by LCMS after 3h), the title compound was isolated as a colorless oil (48 mg, 34%). (After column


chromatography, the title compound was further purified by prep. HPLC 50:50 MeCN:H₂O to 100:0 MeCN:H₂O to remove unidentified impurities.) Note: Reactions conducted below 100 °C failed to provide significant amounts of product by LCMS. Reaction was conducted a single time.

IR (neat, cm⁻¹): 3058, 1596, 1454, 1208.

¹H NMR (500 MHz, CDCl₃): δ 7.54 – 7.44 (m, 4H), 7.37 (t, *J* = 7.5 Hz, 2H), 7.34 – 7.26 (m, 4H), 7.22 – 7.15 (m, 2H), 7.12 (td, *J* = 7.7, 1.2 Hz, 1H), 6.93 (t, *J* = 7.2 Hz, 1H), 6.82 (d, *J* = 8.0 Hz, 1H), 6.33 (s, 1H).

¹³C NMR (125 MHz, CDCl₃): δ 151.51, 138.57, 137.30, 133.13, 129.55, 128.82, 128.73, 128.71, 128.15, 128.04, 127.03, 125.55, 123.00, 121.57, 121.13, 116.59, 77.80.

HRMS: (ESI-TOF) calculated for C₂₁H₁₇O ([M+H]⁺): 285.1274, found: 285.1271.




Prepared according to the general procedure (40 °C, 10 mol% PPh₃, complete conversion by LCMS after 2h), the title compound was isolated as a yellow oil (Run #1: 111 mg, 80%, Run #2: 117 mg, 85%).

IR (neat, cm⁻¹): 3050, 2827, 1477, 1197.

¹H NMR (500 MHz, CDCl₃): δ 7.42 – 7.35 (m, 4H), 7.09 (dd, *J* = 8.5, 2.3 Hz, 1H), 7.03 (d, *J* = 2.3 Hz, 1H), 6.73 (d, *J* = 8.6 Hz, 1H), 6.54 (d, *J* = 9.8 Hz, 1H), 5.91 (s, 1H), 5.86 (dd, *J* = 9.8, 3.5 Hz, 1H).

¹³C NMR (125 MHz, CDCl₃): δ 151.42, 138.68, 134.58, 129.30, 129.04, 128.61, 126.35, 126.15, 125.58, 123.64, 122.59, 117.48, 76.52.

HRMS: (ESI-TOF) calculated for C₁₅H₁₁Cl₂O ([M-H]⁺): 275.0030, found: 275.0029.




Prepared according to the general procedure (40 °C, 10 mol% PPh₃, complete conversion by LCMS after 2h), the title compound was isolated as a white solid (Run #1: 131 mg, 88%, Run #2: 135 mg, 90%).

IR (neat, cm^{-1}): 3040, 2903, 1603, 1453.

^1H NMR (500 MHz, CDCl_3): δ 7.97 (dd, $J = 24.1, 7.6$ Hz, 2H), 7.63 (t, $J = 8.2$ Hz, 2H), 7.51 (t, $J = 7.7$ Hz, 1H), 7.40 (t, $J = 7.5$ Hz, 1H), 7.36 (t, $J = 7.6$ Hz, 1H), 7.17 (t, $J = 7.4$ Hz, 1H), 7.09 (d, $J = 7.2$ Hz, 1H), 6.93 (t, $J = 7.4$ Hz, 1H), 6.87 (d, $J = 8.0$ Hz, 1H), 6.68 (s, 1H), 6.65 (d, $J = 9.9$ Hz, 1H), 6.03 (dd, $J = 9.8, 3.6$ Hz, 1H).

^{13}C NMR (125 MHz, CDCl_3): δ 156.28, 153.34, 153.00, 129.64, 127.41, 126.83, 125.52, 124.84, 124.65, 124.41, 124.25, 123.93, 123.11, 123.00, 121.47, 121.45, 120.85, 120.70, 116.20, 112.00, 71.90.

HRMS: (ESI-TOF) calculated for $\text{C}_{21}\text{H}_{15}\text{O}_2$ ($[\text{M}+\text{H}]^+$): 299.1067, found: 299.1073.



Prepared according to the general procedure (40 °C, 10 mol% PPh_3 , complete conversion by LCMS after 30 min), the title compound was isolated as a colorless solid (Run #1: 138 mg, 88%, Run #2: 142 mg, 90%).

IR (neat, cm^{-1}): 3057, 2873, 1604, 1483.

^1H NMR (500 MHz, CDCl_3): δ 8.22 – 8.10 (m, 2H), 7.93 – 7.81 (m, 1H), 7.55 (d, $J = 7.3$ Hz, 1H), 7.52 – 7.44 (m, 3H), 7.14 (td, $J = 8.1, 1.1$ Hz, 1H), 7.08 (d, $J = 7.4$ Hz, 1H), 6.92 (t, $J = 7.4$ Hz, 1H), 6.86 (d, $J = 8.0$ Hz, 1H), 6.66 (dd, $J = 9.8, 1.7$ Hz, 1H), 6.33 – 6.24 (m, 1H), 5.90 (dd, $J = 9.8, 3.1$ Hz, 1H).

^{13}C NMR (125 MHz, CDCl_3): δ 153.39, 139.87, 137.87, 136.73, 135.43, 134.94, 129.73, 127.02, 126.92, 125.52, 124.82, 124.53, 123.39, 122.84, 121.79, 121.77, 121.69, 121.50, 116.22, 76.76. One peak is obscured due to overlap.

HRMS: (ESI-TOF) calculated for $\text{C}_{21}\text{H}_{15}\text{OS}$ ($[\text{M}+\text{H}]^+$): 315.0838, found: 315.0833.


III. Procedure for gram scale synthesis of 2-phenyl-2*H*-1-benzopyran

A 25-mL RBF equipped with a PTFE-coated stir-bar was brought into a N₂ filled glovebox, charged with Ni(cod)₂ (137 mg, 0.50 mmol, 5 mol%) and PPh₃ (131 mg, 0.50 mmol). 1,4-dioxane (6 mL) was added via micropipette and the resulting orange suspension stirred until mostly homogenous (15 min, dark blood red solution was formed). The flask was tightly sealed with a rubber septum and further sealed with electrical tape. It was removed from the glovebox and placed on an N₂ line.

2-ethoxy-2*H*-chromene (10 mmol, 1.76 g) was transferred to a N₂-flushed 100 mL pear-shaped Schlenk flask and degassed (15 min, N₂ sparge, with stirring). PhB(OH)₂ (20 mmol, 2.43 g) was quickly added and the flask subjected to three evac/purge cycles with N₂. The mixture was dissolved (46 ml 1,4-dioxane, 4 ml *t*-AmOH, 0.2M with respect to 2-ethoxy-2*H*-chromene) and stirred for 30 secs. The blood red catalyst mixture was added via syringe (catalyst flask was rinsed with an additional 2 mL of 1,4-dioxane to ensure complete transfer) and the resulting mixture placed into a preheated oil bath (40 °C). After 14 h the reaction appears to stagnate (no further conversion of SM is observed by LCMS). The reaction mixture is directly concentrated and subjected to column chromatography (100 g silica, 0->20% CH₂Cl₂/hexanes) to give a mixed fraction containing 4-phenyl-4*H*-1-benzopyran (1,4 adduct) and 2-phenyl-2*H*-1-benzopyran (1,2 adduct) (250 mg, 3:1 ratio by ¹H NMR) followed by a clean fraction containing the desired product (1,2 adduct) (1.47 g, >20:1 rr) (overall yield of 1.72 g, 8:1 rr, 85%).


*Note that the rr resulting from this scaled-up reaction is lower than that with the 0.5 mmol reactions as a result of the more concentrated reactions conditions (0.2M rather than 0.02M).

1,2-adduct:



Matches previously recorded information. Labrosse, J. R.; Lhoste, P.; Sinou, D. *Synthetic Communications*, **2002**, *32*, 3667.

1,4-adduct:




Matches previously recoded information. Hall, S. S.; Farahat, S. E. *J. Heterocyclic Chem.* **1987**, *24*, 1205.

IV. Procedure for the late stage addition of aryl boronic acids to chromene acetals

A 2-dram vial equipped with a PTFE-coated stir-bar and PTFE-tape-lined screw-thread was brought into a N₂ filled glovebox, charged with Ni(cod)₂ (2.75 mg, 0.01 mmol, 10 mol%) and PPh₃ (7.8 mg, 0.05 mmol, 10 mol% or 30 mol%). 1,4-dioxane (200 μL) was added via micropipette and the resulting orange suspension stirred until complete dissolution (15 min, dark blood red solution was formed). This solution was then added via micropipette to a solution (previously prepared in a 20 mL screw cap test tube) of the corresponding boronic acid (0.20 mmol, 2 equiv) and 2-ethoxy-2*H*-chromene (17 mg, 0.10 mmol) in dioxane/*t*-AmOH (10:1, 5 mL total, 0.02M with respect to 2-ethoxy-2*H*-chromene). The tube was then sealed with a teflon lined screw cap, and further wrapped with electrical tape. The tube was then removed from the glovebox and immediately placed into a preheated oil bath (100 °C) and aged until LCMS indicated the reaction has stalled or reached complete conversion.

After this time, the reaction mixture was concentrated and the crude subjected to flash chromatography.




Prepared according to the general procedure (the reaction is observed to stall after 3 h by LCMS), the title compound was isolated as a pale yellow oil (12 mg, 26%). (After column chromatography, the title compound was further purified by prep. HPLC 50:50 MeCN:H₂O to 100:0 MeCN:H₂O to remove protodeborylated material.)

IR (neat, cm⁻¹): 2994, 1736, 1681, 1478.

¹H NMR (500 MHz, CDCl₃): δ 7.72 (d, *J* = 8.3 Hz, 2H), 7.57 (d, *J* = 8.1 Hz, 2H), 7.15 (td, *J* = 7.9, 1.5 Hz, 1H), 7.03 (dd, *J* = 7.4, 1.4 Hz, 1H), 6.95 (d, *J* = 2.4 Hz, 1H), 6.92 – 6.87 (m, 2H), 6.83 (d, *J* = 8.0 Hz, 1H), 6.65 (dd, *J* = 9.0, 2.5 Hz, 1H), 6.57 (dd, *J* = 9.8, 1.3 Hz, 1H), 6.01 (s, 1H), 5.82 (dd, *J* = 9.8, 3.4 Hz, 1H), 3.84 (s, 3H), 3.70 (s, 3H), 3.67 (s, 2H), 2.37 (s, 3H).

¹³C NMR (125 MHz, CDCl₃): δ 171.48, 169.08, 155.95, 152.89, 145.80, 136.07, 135.33, 130.91, 130.59, 130.18, 129.77, 127.07, 126.83, 124.59, 124.05, 121.61, 121.19, 116.04, 115.12, 112.28, 111.57, 101.13, 76.38, 55.75, 52.23, 30.21, 13.46.

HRMS: (ESI-TOF) calculated for C₂₉H₂₅NO₅ ([M+H]⁺): 468.1805, found: 468.1801.



Prepared according to the general procedure (after 30 min, the reaction appears complete by LCMS), the title compound was isolated as a thick yellow oil (21 mg, 56%).


IR (neat, cm^{-1}): 3060, 2833, 1675, 1485.

^1H NMR (500 MHz, CDCl_3): δ 9.72 (s, 1H), 8.03 (s, 1H), 7.88 (d, J = 8.2 Hz, 1H), 7.68 (d, J = 8.2 Hz, 1H), 7.38 (d, J = 3.7 Hz, 1H), 7.14 (td, J = 7.9, 1.5 Hz, 1H), 7.10 – 7.02 (m, 2H), 6.92 (t, J = 7.4 Hz, 1H), 6.77 (d, J = 8.1 Hz, 1H), 6.65 (dd, J = 9.8, 1.5 Hz, 1H), 6.33 – 6.26 (m, 1H), 5.75 (dd, J = 9.8, 3.3 Hz, 1H).

^{13}C NMR (125 MHz, CDCl_3): δ 177.80, 156.10, 153.04, 152.59, 141.36, 131.11 (q, J = 33.0 Hz), 130.02, 129.75, 128.77, 126.56 | 21
.13,
116.12, 113.18, 73.27.

^{19}F NMR (282 MHz, CDCl_3): δ -62.79.

HRMS: (ESI-TOF) calculated for $\text{C}_{21}\text{H}_{13}\text{F}_3\text{O}_3$ ($[\text{M}+\text{H}]^+$): 371.0890, found: 371.0899.



Prepared according to the general procedure (after 10 min, the reaction appears complete by LCMS), the title compound was isolated as a white foam (38 mg, 79%).

IR (neat, cm^{-1}): 3045, 2907, 1691, 1205.

^1H NMR (500 MHz, CDCl_3): δ 8.38 (d, J = 4.3 Hz, 1H), 7.43 (d, J = 7.7 Hz, 1H), 7.30 - 7.23 (m, 3H), 7.22 - 7.17 (m, 1H), 7.13 - 7.06 (m, 2H), 7.00 (d, J = 7.4 Hz, 1H), 6.86 (t, J = 7.4 Hz, 1H), 6.77 (d, J = 8.0 Hz, 1H), 5.86 (s, 1H), 5.75 (d, J = 9.9 Hz, 1H), 4.13 (q, J = 7.0 Hz, 2H), 3.81 (s, 2H), 3.46 - 3.29 (m, 2H), 3.15 - 3.05 (m, 2H), 2.89 - 2.79 (m, 2H), 2.47 (s, 1H), 2.37 (s, 2H), 2.32


(s, 1H), 1.25 (t, $J = 7.1$ Hz, 3H).

^{13}C NMR (125 MHz, CDCl_3): δ 161.86, 155.54, 153.15, 146.64, 139.97, 137.48, 137.43, 137.03, 134.98, 133.65, 129.78, 129.66, 129.51, 127.93, 127.87, 126.66, 124.94, 124.87, 124.80, 124.75, 124.06, 122.21, 121.25, 121.22, 115.96, 61.35, 44.91, 31.94, 31.69, 31.63, 14.74.

HRMS: (ESI-TOF) calculated for $\text{C}_{31}\text{H}_{31}\text{N}_2\text{O}_3$ ($[\text{M}+\text{H}]^+$): 479.2329, found: 479.2341.

V. Procedure for preparation of complex aryl boronic acids

Procedures adapted from: Molander, G. A.; Trice, S. L. J.; Dreher, S. D. *J. Am. Chem. Soc.* **2010**, *132*, 17701.




A 100 mL pear-shaped schlenk flask fitted with a magnetic stirbar was sequentially charged with 5-(2-Chloro-5-trifluoromethylphenyl)furfural (1.37 g, 5.00 mmol), 2-amino-biphenyl Pd-XPhos precatalyst (78.5 mg, 0.10 mmol, 2 mol%), XPhos (95.0 mg, 0.20 mmol, 4 mol%), $B_2(OH)_2$ (672 mg, 7.50 mmol, 1.5 eq), KOAc (1.47 g, 15.0 mmol, 3.0 eq), NaOtBu (9.0 mg, 0.10 mmol, 2 mol%) and the vessel sealed with rubber septum. The vessel was subject to 3 evac/purge cycles with N_2 and then charged with 50 mL of EtOH (previously degassed with sonication under a N_2 sparge, 20 mins). The resulting mixture was placed into a pre heated oil bath (80 °C) and aged with vigorous stirring. After 2.5 h LCMS analysis indicates the complete consumption of starting material ($[M-F]^- = 256$, negative ionization mode, APCI/ESI) with formation of product ($[M-H+HCO_2H]^- = 329$, negative ionization mode, APCI/ESI) and production of two unidentified major side products ($[M]^- = 331$, and $[M]^- = 568$). The reaction mixture is cooled to r.t. and filtered through a short pad of celite. The resulting mixture is taken up in 100 mL 1N HCl/EtOAc (1:1 v/v) and stirred for 5 min. The layers are separated, and the organic phase washed with brine. Combined aqueous phases were extracted (1x50 mL, EtOAc) and the resulting organic layers combined and dried (Na_2SO_4). After concentration under reduced pressure, the resulting orange foam is taken up in a minimal amount of MeCN and applied to a slurry packed column of C18 silica (50:50 MeCN:H₂O) and eluted (50:50 MeCN:H₂O) to give 4 bright yellow fractions (~50 mL each). The first two fractions are combined and concentrated slowly under reduced pressure. Once the MeCN is removed a yellow slurry results with small amount of orange oil (failure to remove this impurity prevents successful execution of the next step). The orange oil is decanted and the yellow slurry concentrated to give an amorphous solid that is contaminated with unidentified impurities (LCMS). The resulting solid is suspended in 2 mL of MTBE:hexanes (1:1 v/v) and stirred for 5 minutes. The bright yellow/orange suspension is allowed to settle and the solvent decanted. The process is repeated and the resulting fine yellow powder is washed once with hexanes and dried under high vacuum to give the desired product (350 mg, ~25% yield).

IR (neat, cm^{-1}): 3298, 1661, 1332, 1089.

1H NMR (300 MHz, DMSO): δ 9.64 (s, 1H), 8.47 (s, 2H), 8.07 (s, 1H), 7.75 (dd, $J = 7.8, 1.0$ Hz, 1H), 7.70 (s, 1H), 7.67 (d, $J = 3.8$ Hz, 1H), 7.24 (d, $J = 3.8$ Hz, 1H).

¹³C NMR (126 MHz, DMSO): δ 178.12, 158.37, 152.20, 141.53, 133.58, 131.68, 129.43 (q, *J* = 32.1 Hz), 124.87, 124.22 (q, *J* = 272.2 Hz), 122.34, 110.53. (C-B carbon not observed).

HRMS: (ESI-TOF) calculated for C₁₂H₉BF₃O₄ ([M+H]⁺): 285.0541, found: 285.0544.




A 50 mL pear-shaped schlenk flask fitted with a magnetic stirbar was sequentially charged with loratadine (382 mg, 1.00 mmol), 2-amino-biphenyl Pd-XPhos precatalyst (19.6 mg, 0.025 mmol, 2.5 mol%), XPhos (23.8 mg, 0.50 mmol, 5 mol%), B₂(OH)₂ (268 mg, 3.00 mmol, 3.0 eq), KOAc (294 mg, 3.0 mmol, 3.0 eq), NaOtBu (2.5 mg, 0.025 mmol, 2.5 mol%) and the vessel sealed with rubber septum. The vessel was subject to 3 evac/purge cycles with N₂ and then charged with 20 mL of EtOH (previously degassed with sonication under a N₂ sparge, 20 mins). The resulting mixture was placed into a pre heated oil bath (80 °C) and aged with vigorous stirring. After 3 h LCMS analysis indicates the complete consumption of starting material (observed [M+1] in positive mode APCI/ESI) with formation of product (observed [M+1] in positive mode APCI/ESI). The reaction mixture is cooled to r.t. and filtered through a short pad of celite. The resulting mixture is taken up in 50 mL 1N HCl/EtOAc (1:1 v/v) and stirred for 30 min. The layers are separated, and the aqueous phase washed (2x25 mL, EtOAc) and the combined organics discarded. The pH of the aqueous phase is adjusted (ph>11, addition of 10N NaOH) and the resulting slurry extracted (3x50 mL EtOAc). The combined organics were washed with brine, dried (Na₂SO₄), and concentrated to give a yellow solid (~85LCAP). The solid was dissolved in a minimal amount of CH₂Cl₂ and hexanes were slowly added with stirring until a fine white powder was observed. The powder was collected via vacuum filtration and washed with hexanes. The resulting white powder was dried for 3h under high vacuum to give the desired product as a mixture of boroxine and boronic acid (>95LCAP, 250 mg, 63%).

IR (neat, cm⁻¹): 3406, 2978, 1678, 1340.

¹H NMR (300 MHz, DMSO): δ 8.33 (d, *J* = 3.6 Hz, 1H), 8.00 (s, 2H), 7.65 – 7.52 (m, 3H), 7.19 (dd, *J* = 7.4, 4.8 Hz, 1H), 7.03 (d, *J* = 7.5 Hz, 1H), 4.03 (q, *J* = 7.0 Hz, 2H), 3.67 – 3.56 (m, 2H), 3.36 – 3.27 (m, 2H), 3.17 (broad s, 2H), 2.88 – 2.73 (m, 2H), 2.35 – 2.25 (m, 2H), 2.25 – 2.10 (m, 2H), 1.17 (t, *J* = 7.1 Hz, 3H).

¹³C NMR (126 MHz, DMSO): δ 157.72, 154.98, 146.68, 140.98, 137.86, 136.83, 135.97, 135.79, 135.25, 134.03, 131.96, 128.53, 122.77, 61.17, 44.97, 44.88, 31.81, 31.41, 30.78, 30.69, 15.11. (C-B carbon not observed).

HRMS: (ESI-TOF) calculated for C₂₂H₂₅BN₂O₄ ([M+H]⁺): 393.1980, found: 393.1989.



A 50 mL pear-shaped schlenk flask fitted with a magnetic stirbar was sequentially charged with indomethacin methyl ester (1 g, 2.92 mmol), 2-amino-biphenyl Pd-XPhos precatalyst (22 mg, 0.020 mmol, 1.0 mol%), XPhos (27 mg, 0.050 mmol, 2 mol%), $B_2(OH)_2$ (392 mg, 4.38 mmol, 1.5 eq), KOAc (859 mg, 8.76 mmol, 3.0 eq), NaOtBu (2.8 mg, 0.020 mmol, 1.0 mol%) and the vessel sealed with rubber septum. The vessel was subject to 3 evac/purge cycles with N_2 and then charged with 29 mL of EtOH (previously degassed with sonication under a N_2 sparge, 20 mins). The resulting mixture was placed into a pre heated oil bath (80 °C) with vigorous stirring and aged for 3 h. After this time, LCMS analysis indicates the complete consumption of starting material (observed $[M+1]$ in positive mode APCI/ESI) with formation of product (observed $[M+1]$ in positive mode APCI/ESI). The reaction proceeds from yellow to green during this time period. The reaction mixture is cooled to r.t. and filtered through a short pad of celite. The resulting crude mixture is taken up in 200 mL 1N HCl/EtOAc (1:1 v/v) and stirred for 30 min. The layers are separated, and the aqueous phase extracted (1x50 mL, EtOAc). The combined organics were then washed with brine, and dried (Na_2SO_4). Concentration under reduced pressure gives a yellow foam, observed to contain both the desired material (Boronic acid) and an impurity resulting from dimerization of the aryl chloride (LCMS, obs. $[M+1]$ in positive mode APCI/ESI). The solid was dissolved in ~50 mL of CH_2Cl_2 and hexanes were slowly added with stirring until a fine white powder was observed. The powder was collected via vacuum filtration and washed several times with hexanes. The resulting white powder was dried for 3h under high vacuum to give the desired product as a mixture of boroxine and boronic acid (>95LCAP, 354 mg, 32%).

IR (neat, cm^{-1}): 3412, 2954, 1736, 1662.


1H NMR (500 MHz, DMSO): δ 8.40 (s, 2H), 7.94 (d, $J = 7.9$ Hz, 2H), 7.60 (d, $J = 8.0$ Hz, 2H), 7.02 (d, $J = 2.3$ Hz, 1H), 6.85 (d, $J = 9.0$ Hz, 1H), 6.68 (dd, $J = 9.0, 2.3$ Hz, 1H), 3.78 (s, 2H), 3.75 (s, 3H), 3.62 (s, 3H), 2.20 (s, 3H).

^{13}C NMR (126 MHz, DMSO): δ 171.12, 169.13, 155.45, 136.55, 135.49, 134.35, 130.44, 130.21, 127.99, 114.53, 112.48, 111.27, 101.44, 55.35, 51.82, 29.06, 13.14. (C-B carbon not observed).

HRMS: (ESI-TOF) calculated for $C_{20}H_{21}BNO_6$ ($[M+H]^+$): 382.1456, found: 382.1453.

VI. Preparation of Acetals

Chromene acetals were prepared from their corresponding coumarins in direct analogy to previously reported methods: Moquist, P. N.; Kodama, T.; Schaus, S. E. *Angew. Chem., Int. Ed. Engl.* **2010**, *49*, 7096.




$^1\text{H NMR}$ (500 MHz, CDCl_3): δ 6.91 (dd, $J = 6.7, 1.9$ Hz, 2H), 6.85 (dt, $J = 8.3, 1.8$ Hz, 1H), 6.67 (d, $J = 9.7$ Hz, 1H), 5.93 (dd, $J = 9.7, 3.8$ Hz, 1H), 5.66 (d, $J = 3.8$ Hz, 1H), 3.93 (dq, $J = 9.7, 7.1$ Hz, 1H), 3.66 (dq, $J = 9.7, 7.1$ Hz, 1H), 1.20 (t, $J = 7.1$ Hz, 3H).

$^{13}\text{C NMR}$ (125 MHz, CDCl_3): δ 158.36, 156.46, 147.27 (d, $J = 2.0$ Hz), 125.91, 121.61 (d, $J = 8.5$ Hz), 117.55 (d, $J = 8.1$ Hz), 115.72 (d, $J = 23.5$ Hz), 113.01 (d, $J = 23.7$ Hz), 94.81, 63.82, 15.30.

$^{19}\text{F NMR}$ (282 MHz, CDCl_3): δ -123.19.


LRMS (APCI/ESI): calculated for $\text{C}_9\text{H}_6\text{FO}$ ($[\text{M-OEt}]^+$): 149, found: 149.



$^1\text{H NMR}$ (500 MHz, CDCl_3): δ 7.01 (d, $J = 7.7$ Hz, 1H), 6.94 (s, 1H), 6.86 (d, $J = 8.1$ Hz, 1H), 6.68 (d, $J = 9.6$ Hz, 1H), 5.85 (dd, $J = 9.6, 3.7$ Hz, 1H), 5.66 (d, $J = 3.7$ Hz, 1H), 3.93 (dq, $J = 14.3, 7.1$ Hz, 1H), 3.65 (dq, $J = 14.3, 7.1$ Hz, 1H), 2.28 (s, 3H), 1.19 (t, $J = 7.1$ Hz, 3H).

$^{13}\text{C NMR}$ (125 MHz, CDCl_3): δ 149.35, 130.80, 130.02, 127.54, 126.76, 120.63, 120.10, 116.39, 94.94, 63.56, 20.75, 15.43.


LRMS (APCI/ESI): calculated for $\text{C}_{10}\text{H}_9\text{O}$ ($[\text{M-OEt}]^+$): 145, found: 145.



$^1\text{H NMR}$ (500 MHz, CDCl_3): δ 7.55 (dd, $J = 8.2, 1.0$ Hz, 2H), 7.41 (t, $J = 7.6$ Hz, 2H), 7.33 (t, $J = 7.3$ Hz, 1H), 7.28 – 7.21 (m, 2H), 7.07 – 6.97 (m, 3H), 5.99 (s, 1H), 4.09 – 3.98 (m, 1H), 3.87 – 3.77 (m, 1H), 1.26 (t, $J = 7.1$ Hz, 3H).

^{13}C NMR (125 MHz, CDCl_3): δ 150.26, 136.78, 130.67, 129.27, 128.78, 127.96, 127.52, 125.57, 121.88, 121.79, 121.66, 116.48, 96.99, 63.77, 15.40.

LRMS (APCI/ESI): calculated for $\text{C}_9\text{H}_6\text{FO}$ ($[\text{M}-\text{OEt}]^+$): 207, found: 207.




^1H NMR (500 MHz, CDCl_3): δ 7.16 (dd, $J = 8.6, 2.4$ Hz, 1H), 7.12 (d, $J = 2.3$ Hz, 1H), 6.90 (d, $J = 8.6$ Hz, 1H), 6.66 (d, $J = 9.7$ Hz, 1H), 5.91 (dd, $J = 9.7, 3.7$ Hz, 1H), 5.68 (d, $J = 3.7$ Hz, 1H), 3.97 – 3.88 (m, 1H), 3.71 – 3.61 (m, 1H), 1.20 (t, $J = 7.1$ Hz, 3H).

^{13}C NMR (125 MHz, CDCl_3): 150.05, 129.12, 126.67, 126.33, 125.73, 122.16, 121.30, 118.07, 95.01, 63.95, 15.38.

LRMS (APCI/ESI): calculated for $\text{C}_9\text{H}_6\text{ClO}$ ($[\text{M}-\text{OEt}]^+$): 165, found: 165.

VII. Competition study




The competition reactions were run in a fashion identical to the general procedure for the arylation of chromene acetals with the follow exceptions:


Boronic acids employed in the study were recrystallized from water prior to use ensure reproducible results from batch to batch. In line with previous knowledge, we have observed that commercial samples frequently contain varying amounts of boroxine and boronic acid.

The initial ratios of nucleophile were determined by removing a small aliquot from the reaction mixture prior to the addition of the catalyst solution. The aliquot was concentrated and then analyzed by ^1H NMR. The reaction progress was monitored by LCMS, and was determined to be complete when 2-ethoxy-2*H*-chromene could no longer be detected (<2LCAP). The reaction mixture was then concentrated under reduced pressure to the crude reaction mixture. This was then suspended in CDCl_3 and filtered through a 0.2 μm syringe filter and further diluted with CDCl_3 . Analysis by ^1H NMR allowed the direct determination of the product ratios. Spectra of recrystallized boronic acids, initial ratios of boronic acids and product distributions are included below:


4-trifluoromethylphenyl boronic acid after recrystallization from water (500 MHz, CDCl_3):



phenyl boronic acid after recrystallization from water (500 MHz, CDCl_3):




Pre-reaction ratio of nucleophile (500 MHz, CDCl_3):




Ratio pCF₃ boroxine to Ph boroxine ~ 1:1
Ratio pCF₃ boronic acid to Ph boronic acid ~ 0.20:0.15

Post reaction Product ratio:




Ratio ~ 3.0:0.91 (p-CF₃ product:phenyl product)

4-methoxyphenyl boronic acid after recrystallization from water (500 MHz, CDCl₃):




Pre-reaction ratio of nucleophile:



Ratio pMeO boroxine to Ph boroxine ~ 0.80:0.74



Ratio pMeO boronic acid to Ph boronic acid ~ 0.10:0.15

Post reaction Product ratio:





Ratio ~ 1.0:0.63 (p-CF₃ product:phenyl product)



A2_67-tg-3-116postcolumn
PROTON.PU CDCl3 /opt/topspin tgraham 67





A2_67-tg-3-116postcolumn
C13APT.PU CDCl3 /opt/topspin tgraham





A2_95-tg-3-108postcolumn
PROTON.PU CDCl3 /opt/topspin tgraham 95







A2_95-tg-3-108postcolumn
C13APT.PU CDCl3 /opt/topspin tgraham 95





tg-3-108f19postcolumn
F19 OBSERVE
STANDARD PARAMETERS








A1_70-tg-3-122postcolumn



A3_87-tg-3-122-take2c13




—152.92
—144.79
129.87
127.27
126.91
124.68
124.05
121.67
121.24
116.14

—76.33

A (q)
130.50


B (q)
125.77

C (q)
124.15




tg-3-122-f19postcolumn



F1
ST





---63.01




A3_34-tg-3-102postcolumn




A3_34-tg-3-102postcolumn





tg-3-102postcolumnf19
F19 OBSERVE
STANDARD PARAMETERS





58.17




A3_35-tg-3-103postcolumn








tg-3-103postcolumnf19
F19 OBSERVE
STANDARD PARAMETERS





---58.25




A1_65-tg-3-135postcolumn



A1_65-tg-3-135postcolumn03




A1_19-tg-3-106postcolumn



17




A1_19-tg-3-106postcolumn





17

153.65
135.56
134.29
131.07
129.60
129.30
128.96
126.84
126.51
125.99
125.91
125.44
125.02
124.95
124.18
121.77
121.49
116.31

74.97




A3_109-tg-3-137



A2_80-tg-3-137c13


C13APT.PU CDCl3 / opt/topspin tgraham





- 169.92
- 151.02
- 141.21
- 135.62
- 129.77
- 129.34
- 127.19
- 126.85
- 124.50
- 124.34
- 121.57
- 121.33
- 116.13

76.54


27.02



A1_18-tg-3-105postcolumn




A1_18-tg-3-105postcolumn





153.30
138.18
133.43
133.33
129.68
128.76
128.33
127.83
126.79
126.38
126.20
125.09
124.84
124.39
121.48
121.38
116.17


77.40



A3_108-tg-3-136




A2_79-tg-3-136c13
C13APT.PU CDCl3





166.73
161.95
155.03
147.72
131.50
128.67
125.38
128.58
128.29
126.94
126.80
124.52
124.46
121.46
121.43
116.17



76.72

61.18




A1_69-tg-3-120postcolumn






A2_70-tg-3-101-retake
PROTON.PU CDCl3 /opt/topspin tgraham 70




14




A2_70-tg-3-101-retake/11



C13APT.PU CDCl3 /opt/topspin tgraham




14




tg-3-101postcolumnf19
F19 OBSERVE
STANDARD PARAMETERS





A1_71-tg-3-123postcolumn





13



A3_88-tg-3-123-take2c13



tg-3-123-f19postcolumn
F19 OBSERVE
STANDARD PARAMETERS



B (m)
-133.89
H

tg-3-123-f19postcolumn
F19 OBSERVE
STANDARD PARAMETERS

A (tt)
3060.08
H

A (tt)
-161.08


0.50
f1 (ppm)

1.01


0.50


-122 -124 -126 -128 -130 -132 -134 -136 -138 -140 -142 -144 -146 -148 -150 -152 -154 -156 -158 -160 -162 -164 -166 -168 -170 -172

f1 (ppm)




24






24




tg-3-100postcolumnf19
F19 OBSERVE
STANDARD PARAMETERS





24



---58.49





A2_71-tg-3-156-retake
PROTON.PU CDCl3 /opt/topspin tgraham 71




A2_71-tg-3-156-retake
C13APT.PU CDCl3 /opt/topspin tgraham




A1_67-tg-3-118postcolumn



A1_67-tg-3-118postcolumn




22




A2_30-tg-3-167-frac1

PR





pspin tgraham 30



A2_30-tg-3-167-frac1


C13APT.PU CDCl3 /opt/topspin/gram 30



tg-dicf3prod-f19

F1

ST




---58.86

---63.20



-56.5 -57.0 -57.5 -58.0 -58.5 -59.0 -59.5 -60.0 -60.5 -61.0 -61.5 -62.0 -62.5 -63.0 -63.5 -64.0 -64.5 -65.0 -65.5 -66.0

f1 (ppm)

12000
11000
10000
9000
8000
7000
6000
5000
4000
3000
2000
1000
0
-1000




A2_86-tg-3-107-postcolfrac2
PROTON.PU CDCl3 /opt/topspin tgraham 86




A2_77-tg-3-107postcolumn

C1





t/topspin

151.59
138.40
138.06
133.97
129.54
128.46
127.84
126.72
126.34
124.68
124.61
121.54
121.29
116.06





A2_88-tg-3-131

PROTON.PU CDCl3 /opt/topspin tgraham 88






A2_88-tg-3-131

C1




A1_120-tg-3-130postcolumn






164.48
152.82
146.06
138.18
129.77
128.96
126.80
124.91
123.98
121.52
121.42
116.30
111.26
74.64
53.68





A2_119-tg-3-190-postHPLC

PR spin tgraham 119





A2_64-tg-3-190posthpt
C13APT.PU CDCl3 /opt/topspin tgraham 64




A2_56-tg-3-189postcolumn
PR

in tgraham 56



A2_56-tg-3-189postcolumn
C1




152.41
148.81
138.42
136.06
135.18
127.09
125.63
122.71
122.07
121.12
116.31

73.97

A (q)
148.07
H

C (q)
121.54


B (q)
120.59



tg-3-189-postcolumnf19

F1


ST





28

¹⁹F NMR (376 MHz, CDCl₃) δ -68.32.



---68.32





A2_96-tg-3-148postcolumn
PROTON.PU CDCl3 /opt/topspin tgraham 96



A2_96-tg-3-148postcolumn
C13APT.PU CDCl3 /opt/topspin tgraham 9




A1_101-tg-3-145postcolumn



A2_116-tg-3-145postcolumn

C1




opspin tgraham 116




tg-3-145postcolumn-f19

F1
ST





^{19}F NMR (376 MHz, CDCl_3) δ -123.66.

-123.66




A3_87-tg-3-147postcolumn






A2_85-tg-3-147postcolumn

C1




spin tgraham 85
151.70
144.28
128.14
128.88
128.74
127.19
126.26
126.17
125.93
123.25
122.71
117.44





A2_91-tg-3-150postcolumn
C1




155.46
148.00
128.80
128.51
127.40
127.20
123.77
121.99
114.74

107.14
101.89


77.44

55.46




A2_65-tg-3-172posthplc

PR topspin tgraham 65




34




A2_65-tg-3-172posthplc

C1





151.51
136.57
134.30
134.13
128.55
128.82
128.73
128.71
128.15
128.04
127.03
125.55
123.00
121.57
121.13
116.59

77.80




A2_87-tg-3-158frac1-postcolumn

PR in tgraham 87




A2_87-tg-3-158frac1-postcolumn

C1





151.49
138.68
138.58
129.30
129.04
128.61
126.35
126.15
125.58
123.64
122.59
117.48




A2_78-tg-3-115postcolumn

PR pt/topspin tgraham 78



A2_78-tg-3-115postcolumn

C1



155.23

153.37

151.00

126.64

124.41

122.83

122.52

121.84

124.65

124.41

124.25

123.93

123.11

123.00

121.47

121.45


120.85

120.70

116.20


112.00

71.90




A2_66-tg-3-114postcolumn

PR dt/topspin tgraham 66




20




A2_66-tg-3-114postcolumn

C1





t/topspin t/gram: 66





tg-3-149postcolumntake2

ST


↓ PARAMETERS





tg-3-149topspot
STANDARD PROTON PARAMETERS





fraction containing 1,2 and 1,4 isomer





A2_62-tg-3-211-indomethprod
PROTON.PU CDCI3 /opt/topspin tgraham 62





A2_62-tg-3-211-indomethro
C13APT.PU CDCl3 /opt/topspin for graham








A2_60-tg-3-212-postcolumn
PROTON.PU CDCl3 /opt/topspin tgraham 60





A2_60-tg-3-2012-postcolumn
C13APT.PU CDCl3 /opt/topspin/





A2_22-tg-3-208-analyticalprod
PROTON.PU CDCl3 /opt/topspin tgraham 22




A2_22-tg-3-208-analytical prod
C13APT.PU CDCl3 /opt/topspin/graham









A2_22-tg-3-208-analyticalprod/11
COSYGPSW.PU CDCl3 /opt/topspin tgraham 22




NB3_tg-3-213-cleanprod



A2_70-tg-3-1213-pure13
C13APT.PU DMSO /opt/topspin/tgraham 70





NB3_tg-3-213-cleanprod1





---6.1.35


A2_111-tg-3-207analyDMSO
C13APT.PU DMSO /opt/topspin/graham




A2_110-tg-3-206analyDMSO
PROTON.PU DMSO /opt/topspin tgraham 110



A2_110-tg-3-206analyDMSO
C13APT.PU DMSO /opt/topspin tgraham 1





tg-3-140postcolumn
ST




PARAMETERS




A2_46-tg-3-4chromeneae
C1 t/tpoin tgraham 46



tg=3-140postcolumnf19





^{19}F NMR (376 MHz, CDCl_3) δ -123.19.





A2_102-tg-3-139-postcolumn

PR topspin tgraham 102





A2_102-tg-3-139-postcolumn



C1 opspin graham 102





A2_117-tg-3-phenylchromacetal
PR /topspin tgraham 117



A2_117-tg-3-phenylchromacetel/11
C1 topspin (g) 400



A1_36-ML-1-7



A2_76-tg-chloroacetal
C13APT.PU CDCl3 /opt/topspin tgraham 7

